Mechanisms that regulate erythroid differentiation of hematopoietic stem cells
造血干细胞红系分化的调节机制
基本信息
- 批准号:10647781
- 负责人:
- 金额:$ 58.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAnemiaBiological AssayBlood CellsBone MarrowBone Marrow TransplantationCell LineageCuesDNADioxygenasesDiseaseErythrocytesErythroidErythropoiesisExhibitsGene ExpressionGenesHematopoiesisHematopoieticHematopoietic Stem Cell heterogeneityHematopoietic SystemHematopoietic stem cellsHemolytic AnemiaHemorrhageHeterogeneityHomeostasisHypoxiaIn VitroInflammationIronIron Chelating AgentsIron ChelationLabelMediatingMetabolicModelingMusNatural regenerationPhosphorylationPhosphotransferasesPopulationProteinsRegenerative MedicineResearchRoleShapesSignal TransductionSourceSpleenStressTFRC geneTestingTransfusionTransplantationalpha ketoglutaratecell typechemotherapycofactordemethylationdesignerythroid differentiationexperimental studyhematopoietic stem cell expansionhematopoietic stem cell fatein vivoinjury recoveryinsightnovelnovel strategiesnovel therapeutic interventionpreventprotein expressionresponseself-renewalsingle-cell RNA sequencingstem cellsstressoruptake
项目摘要
Hematopoietic stem cells (HSCs) are capable of regenerating the entire hematopoietic system. This capacity is
fully unleashed upon bone marrow transplantation, however, recent studies including ours indicate that HSCs
have a much more limited contribution to hematopoiesis during homeostasis. While stress from sources like
chemotherapies or inflammation increases the contribution from HSCs to multiple hematopoietic lineages, little
is known about how HSCs respond to stressors that cause anemia. Identifying the progenitor cell population and
signals that promote erythroid regeneration may lead to novel strategies to better harness HSCs for the treatment
of anemia and regenerative medicine overall. Using a HSC lineage tracing model, we found that hemolytic
anemia specifically enhances erythroid contribution by HSCs, indicating that HSCs respond to erythroid stress
by initiating erythropoiesis. After hemolytic anemia, HSCs expressed more erythropoiesis-related genes and
exhibited enhanced erythroid differentiation in vitro and in vivo. Interestingly, HSCs had increased iron content
after hemolytic anemia and iron chelation prevented erythroid-biased differentiation. Iron is a cofactor for the
iron(II)/α-ketoglutarate-dependent dioxygenase TET2 that demethylates DNA, and erythropoiesis is associated
with DNA demethylation. We found that TET2 protein, but not mRNA, is increased in HSCs during anemia and
deletion of Tet2 suppressed the enhanced erythroid differentiation of HSCs we observed following hemolytic
anemia. We thus hypothesized that HSCs respond to anemia by increasing iron uptake, TET2 expression, and
DNA demethylation, thereby increasing the expression of erythropoiesis genes. In Aim 1, we will study the
heterogeneity of splenic HSCs during anemia and identify the erythroid-biased fraction of HSCs. In Aim 2, we
will examine the role of TET2 in promoting erythroid commitment of splenic HSC. In Aim 3, we will investigate
the mechanism by which TET2 protein is stabilized in HSCs during anemia. Completion of this study will provide
novel insights into the differences between bone marrow and splenic HSCs in responding to anemia, and the
mechanism by which iron and TET2 instructs HSCs to become committed to the erythroid lineage.
造血干细胞(HSC)能够再生整个造血系统。
然而,最近的研究(包括我们的研究)表明,HSC 在骨髓移植后完全释放
在体内平衡过程中,对造血的贡献要有限得多,而来自等来源的压力。
化疗或炎症会增加 HSC 对多种造血谱系的贡献,但影响很小
了解 HSC 如何应对导致贫血的压力源并识别祖细胞群。
促进红细胞再生的信号可能会导致更好地利用造血干细胞进行治疗的新策略
使用 HSC 谱系追踪模型,我们发现溶血性与再生医学的整体关系。
贫血特别增强 HSC 的红细胞贡献,表明 HSC 对红细胞应激有反应
溶血性贫血后,HSC 表达更多的红细胞生成相关基因,并启动红细胞生成。
提示,HSC 铁含量增加,在体外和体内表现出增强的红系分化。
溶血性贫血和铁螯合阻止了红系偏向分化后,铁是红系的辅助因子。
铁 (II)/α-酮戊二酸依赖性双加氧酶 TET2 使 DNA 去甲基化,与红细胞生成相关
我们发现,在贫血和贫血期间,HSC 中的 TET2 蛋白(而非 mRNA)增加。
Tet2 的缺失抑制了我们在溶血后观察到的 HSC 的红系分化增强
因此,我们通过增加铁摄取、TET2 表达和贫血来加强 HSC 对贫血的反应。
DNA 去甲基化,从而增加红细胞生成基因的表达 在目标 1 中,我们将研究
在目标 2 中,我们研究了贫血期间脾 HSC 的异质性并确定了 HSC 的红系偏向部分。
将检查 TET2 在促进脾脏 HSC 的红细胞定型中的作用。在目标 3 中,我们将进行研究。
这项研究的完成将提供贫血期间 TET2 蛋白在 HSC 中稳定的机制。
关于骨髓和脾脏 HSC 在应对贫血方面的差异的新见解,以及
铁和 TET2 指导 HSC 致力于红系谱系的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daisuke Nakada其他文献
Daisuke Nakada的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daisuke Nakada', 18)}}的其他基金
Project 2: The role of the DNA damage response in clonal competition following genotoxic stress
项目 2:DNA 损伤反应在基因毒性应激后克隆竞争中的作用
- 批准号:
10606554 - 财政年份:2022
- 资助金额:
$ 58.21万 - 项目类别:
Mechanisms that regulate erythroid differentiation of hematopoietic stem cells
造血干细胞红系分化的调节机制
- 批准号:
10509652 - 财政年份:2022
- 资助金额:
$ 58.21万 - 项目类别:
Project 2: The role of the DNA damage response in clonal competition following genotoxic stress
项目 2:DNA 损伤反应在基因毒性应激后克隆竞争中的作用
- 批准号:
10332336 - 财政年份:2022
- 资助金额:
$ 58.21万 - 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
- 批准号:
10296885 - 财政年份:2021
- 资助金额:
$ 58.21万 - 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
- 批准号:
10296885 - 财政年份:2021
- 资助金额:
$ 58.21万 - 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
- 批准号:
10434125 - 财政年份:2021
- 资助金额:
$ 58.21万 - 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
- 批准号:
10659193 - 财政年份:2021
- 资助金额:
$ 58.21万 - 项目类别:
Mesenchymal Stromal Cells Regulate Hematopoietic Stem Cell Aging
间充质基质细胞调节造血干细胞衰老
- 批准号:
9189715 - 财政年份:2016
- 资助金额:
$ 58.21万 - 项目类别:
Mesenchymal Stromal Cells Regulate Hematopoietic Stem Cell Aging
间充质基质细胞调节造血干细胞衰老
- 批准号:
9404451 - 财政年份:2016
- 资助金额:
$ 58.21万 - 项目类别:
Metabolic Regulation in Leukemia-Initatiating Cells
白血病起始细胞的代谢调节
- 批准号:
9451935 - 财政年份:2015
- 资助金额:
$ 58.21万 - 项目类别:
相似国自然基金
BeAn 58058病毒影响cofilin 1功能介导重型再生障碍性贫血患者髓样树突状细胞激活及其机制的研究
- 批准号:82300239
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
影响α地中海贫血表型严重性的PIP4K2A基因变异的鉴定及机制研究
- 批准号:82370122
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
骨髓树突状细胞TLR1/2/8-MyD88通路在再生障碍性贫血发生发展中的作用
- 批准号:82370142
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
限食通过下调MS4A3促进红细胞生成的机制研究及其在贫血人群中的临床运用
- 批准号:82360027
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
川芎嗪硝酮衍生物TBN调控缺氧诱导因子治疗肾性贫血的机制
- 批准号:82304597
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Clonal hematopoiesis and inherited genetic variation in sickle cell disease
镰状细胞病的克隆造血和遗传变异
- 批准号:
10638404 - 财政年份:2023
- 资助金额:
$ 58.21万 - 项目类别:
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
- 批准号:
10822502 - 财政年份:2023
- 资助金额:
$ 58.21万 - 项目类别:
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention
帕比司他治疗成人镰状细胞病的 I 期研究:招募和保留的新方法
- 批准号:
10420453 - 财政年份:2023
- 资助金额:
$ 58.21万 - 项目类别:
Small Molecule Therapeutics for Sickle Cell Anemia
镰状细胞性贫血的小分子疗法
- 批准号:
10601679 - 财政年份:2023
- 资助金额:
$ 58.21万 - 项目类别:
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
开发一种新型疾病缓解聚糖疗法,用于镰状细胞病急性血管闭塞危象的早期家庭干预
- 批准号:
10603870 - 财政年份:2023
- 资助金额:
$ 58.21万 - 项目类别: